Revolution Medicines

Our research, now published in Science Magazine, highlights a breakthrough approach to targeting KRAS G12D, the most common oncogenic RAS mutation driving human cancers, which led to the discovery of our investigational RAS(ON) G12D-selective inhibitor.   Read more about this advancement in our release: https://lnkd.in/gUCuRbhd #PrecisionOncology #CancerResearch #KRAS #PancreaticCancer #RASinhibitors

The FDA has granted Breakthrough Therapy Designation to our investigational RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.   This marks the second Breakthrough Therapy Designation for Revolution Medicines’ pipeline, following the designation of our RAS (ON) multi-selective inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with KRAS G12 mutations. We are grateful for the dedication of our team, clinical collaborators, and—most importantly—the patients and families who make this progress possible.   Learn more: https://lnkd.in/gjR7k_YD

Revolution Medicines and Iambic Therapeutics have announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models.    This collaboration presents an exciting opportunity to rapidly explore oncology targets known to be challenging to address through conventional drug discovery approaches.   https://lnkd.in/gEc_wXb7

Revolution Medicines and Summit Therapeutics, Inc. are entering a clinical collaboration to evaluate combinations of our clinical-stage RAS(ON) inhibitors with novel PD-1 VEGF bispecific antibody, across multiple RAS mutant cancers. We are eager to evaluate combinations of investigational drugs from our RAS(ON) inhibitor portfolio with Summit’s advanced PD1 VEGF bispecific inhibitor in a range of RAS mutant cancers. https://lnkd.in/gd7fTqmG

Congratulations Tango Therapeutics on this important milestone. We share your excitement about the potential of these combinations!

We’re proud to announce that Revolution Medicines has partnered with Royalty Pharma on $2 billion in flexible funding to support our independent global development and commercialization strategy and operations. This funding agreement significantly increases the resources we can deploy as we continue our momentum toward establishing new global standards of care and creating value for shareholders. https://lnkd.in/gmnGzgsW

We’re pleased to announce the U.S. FDA has granted Breakthrough Therapy Designation to one of our investigational medicines under evaluation for previously treated metastatic pancreatic adenocarcinoma (PDAC) in patients with KRAS G12 mutations.   This recognition underscores both the urgent need for new treatment options and the potential of novel approaches to target RAS-addicted cancers. More than 90% of patients living with PDAC have tumors carrying a RAS cancer driver mutation with ~85% carrying a KRAS G12 mutation. Should the results of our pivotal trial support it, we’re committed to working closely with the FDA and other regulatory agencies around the world to bring this targeted therapy to patients as quickly as possible. https://lnkd.in/gsAhmvjc

Revolutionaries recently came together for our annual Pride Happy Hour, where employees participated in table discussions and shared reflections on important identities they hold, honoring diverse experiences and highlighting ways to foster a sense of belonging at work. These conversations and our Pride celebration embody our core value of Inclusiveness & Fairness and reinforce our ongoing commitment to a culture where all voices are heard and valued. #PrideMonth #LifeAtRevMed #InclusivenessAndFairness

Thank you to everyone who visited the Revolution Medicines booth and connected with us during #ASCO25. While ASCO has ended, the spotlight on RAS mutations in cancer continues to intensify. With more than 90% of pancreatic ductal adenocarcinoma (PDAC) patients carrying a RAS mutation, there remains a significant need for novel, targeted treatment approaches. Revolution Medicines is dedicated to advancing targeted therapies for patients with RAS-addicted cancers, aiming to improve outcomes and renew hope for patients and their loved ones The collaboration and commitment demonstrated across the oncology community inspires us, and we look forward to building on this momentum together. #Oncology #PancreaticCancer #PDAC

At Revolution Medicines, our mission is deeply personal — and that passion extends beyond the lab. Our team stepped up to honor and support those impacted by cancer through two meaningful events: the Pancreatic Cancer Action Network’s PurpleStride and the AACR Runners for Research Walk in Chicago. Whether walking in memory, in celebration, or in solidarity, our presence at these events reflects the heart behind our science — a commitment to the patients, families, and communities we serve. We are proud to stand with others working to raise awareness, drive research, and move us closer to a world with better outcomes for people living with cancer. #PancreaticCancer #CancerResearch #PanCanPurpleStride #AACR25